Nanae Harashima
Overview
Explore the profile of Nanae Harashima including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
37
Citations
886
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tanino R, Tsubata Y, Harashima N, Harada M, Isobe T
Oncotarget
. 2018 Apr;
9(24):16807-16821.
PMID: 29682186
Pemetrexed (PEM) improves the overall survival of patients with advanced non-small cell lung cancer (NSCLC) when administered as maintenance therapy. However, PEM resistance often appears during the therapy. Although thymidylate...
2.
Iida Y, Harashima N, Motoshima T, Komohara Y, Eto M, Harada M
Cancer Sci
. 2017 Aug;
108(10):1974-1984.
PMID: 28787548
Immune checkpoint blockade is a promising anticancer therapy, but must be used in combination with other anticancer therapies to increase its therapeutic efficacy. Cyclophosphamide (CP) is a chemotherapeutic drug that...
3.
Harashima N, Takenaga K, Akimoto M, Harada M
Oncotarget
. 2017 May;
8(26):42887-42900.
PMID: 28476028
Cancer cells develop resistance to therapy by adapting to hypoxic microenvironments, and hypoxia-inducible factors (HIFs) play crucial roles in this process. We investigated the roles of HIF-1α and HIF-2α in...
4.
Minami T, Matsumura N, Sugimoto K, Shimizu N, De Velasco M, Nozawa M, et al.
Int Immunopharmacol
. 2017 Jan;
44:197-202.
PMID: 28110220
Hypoxic tumor microenvironment makes cancer cells to be therapy-resistant and hypoxia-inducing factors (HIFs) play a central role in hypoxic adaptation. Especially, renal cell carcinoma (RCC) is often associated with von...
5.
Ishikawa S, Matsui Y, Wachi S, Yamaguchi H, Harashima N, Harada M
Cancer Immunol Immunother
. 2016 Jun;
65(8):961-72.
PMID: 27312060
Because cancer is associated with aging, immunological features in the aged should be considered in anticancer immunotherapy. In this study, we investigated antitumor immunity in aged mice using a CT26...
6.
Cherkasova E, Scrivani C, Doh S, Weisman Q, Takahashi Y, Harashima N, et al.
Cancer Res
. 2016 Feb;
76(8):2177-85.
PMID: 26862115
VHL-deficient clear cell renal cell carcinomas (ccRCC), the most common form of kidney cancer, express transcripts derived from the novel human endogenous retrovirus HERV-E (named CT-RCC HERV-E). In this study,...
7.
Hari Y, Harashima N, Tajima Y, Harada M
Oncotarget
. 2015 Oct;
6(39):41902-15.
PMID: 26506422
Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) induces apoptosis in various types of cancer cells without damaging normal cells. However, in terms of pancreatic cancer, not all cancer cells are...
8.
Minami T, Minami T, Shimizu N, Yamamoto Y, De Velasco M, Nozawa M, et al.
J Immunother
. 2015 Aug;
38(7):285-91.
PMID: 26261892
Molecular therapy targeting tumor angiogenesis has been the standard treatment for metastatic renal cell carcinoma (mRCC). However, despite their significant antitumor effects, most of patients with mRCC have not been...
9.
Zhang M, Harashima N, Moritani T, Huang W, Harada M
PLoS One
. 2015 May;
10(5):e0127386.
PMID: 26000607
Death signaling provided by tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) can induce death in cancer cells with little cytotoxicity to normal cells; this cell death has been thought to...
10.
Minami T, Minami T, Shimizu N, Yamamoto Y, De Velasco M, Nozawa M, et al.
Int Immunopharmacol
. 2015 Mar;
26(1):133-8.
PMID: 25819666
Analyses on reactivity of anti-cancer cytotoxic T lymphocytes (CTLs) and clinical application of peptide-based anti-cancer vaccine have been mainly focused on patients with HLA-A2 or -A24 alleles. In this study,...